Publications

1. Yanamandra, K., Jiang, H. Mahan TE et al. (2014) Passive immunization with an antitau antibody reduces insoluble tau and decreases brain atrophy in P301S tau transgenic mice. (Manuscript in review)
2. Yanamandra, K., Kfoury, N., Jiang, H. et al. (2013) Anti-tau antibodies that block tauaggregate seeding in vitro markedly decrease pathology and improve cognition in  vivo.Neuron. 80(2):402-14.
3. Holmes, B.B., DeVos, S.L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K. et al. (2013)Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci. 110(33):E3138-47.
4. Botelho, H.M., Leal, S.S., Cardoso, I, Yanamandra K, Morozova-Roche, L.A. et al.(2012) S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation. J Biol Chem. 287(50) 42233-42.
5. Yanamandra, K., Gruden, M.A., Casaite, V. et al. (2011) α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients. PLoS ONE 6(4): e18513. doi:10.1371/journal.pone.0018513
6. Yanamandra, K., Alexeyev, O., Zamotin, V., Srivastava, V. et al. (2009) AmyloidFormation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate. PLoS ONE 4(5): e5562. doi:10.1371/journal.pone.0005562v.
7. Gruden, M.A., Davidova, T.V., Yanamandra, K. et al. (2013) Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. Behav Brain Res. 243, 205-212.
8. Gruden, M.A., Yanamandra, K., Kucheryanu, V.G. et al. (2012) Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation.19, 334-342.
9. Gruden, M.A., Sewell, R.D., Yanamandra,K. et al (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol. 233, 221-227.
10. Malisauskas M, Weise C, Yanamandra K. et al. (2010) Lability landscape and protease resistance of human insulin amyloid: a new insight into its molecular properties. J Mol Biol. 396, 60-74.
11. Wilhelm, K. R., Yanamandra, K., Gruden, M.A., Zamotin, V. et al. (2007) Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson’s disease patients. Eur j neurol. 14, 327-334.
12. Gharibyan A. L., Zamotin, V., Yanamandra, K., Moskaleva, O. S. et al. (2007) Lysozyme Amyloid Oligomers and Fibrils Induce Cellular Death via Different Apoptotic/Necrotic Pathways. J Mol Biol. 365, 1337-1349.

Book Chapter:

• Chapter 18: Carvalho, S.B., Cardoso, I., Botelho, H.M., Yanamandra, K. et al. Structural heterogeneity and bioimaging of S100 amyloid assemblies. Book: Bionanoimaging: Protein Misfolding and Aggregation (Lyubchenko, Y. & Uversky, V., eds). Elsevier (Publisher).
• Chapter 12: Active and Passive Immunotherapy against Tau: Effects and potential mechanisms. Kiran Yanamandra, Marc I. Diamond, David M. Holtzman. Book: Neurodegenerative disorders - Immunotherapy and Biomarkers (Editors: Lars Lannfelt & Martin Ingelsson). (Chapter submitted)

Papers presented at Conferences:

1. Kiran Yanamandra, Hong Jiang, Tom Mahan, Susan Maloney, David Wozniak, Marc I.Diamond, David M. Holtzman. Passive immunization with an anti-tau antibody reducesinsoluble tau and decreases brain atrophy in P301S tau transgenic mice. AD/PD meeting.Nice, France. March 18-22 2015.
2. K. Dikranian, F. Stewart, M. Levy, K. Yanamandra, and D. M. Holtzman. Theultrastructural cortical pathology of adult P301S tau transgenic mice with neurofibrillarypathology. AD/PD meeting. Nice, France. March 18-22 2015.
3. Kiran Yanamandra, Hong Jiang, Thomas E. Mahan, Susan E. Maloney, David F.Wozniak, Marc I. Diamond, David M. Holtzman. Effects of peripheral administration ofan anti-tau antibody in P301S tau transgenic mice. Cell symposium – TranslationalNeuroscience. Arlington, VA. Nov 13-14 2014.
4. Kiran Yanamandra, Hong Jiang, Tom Mahan, Susan Maloney, David Wozniak, Marc I.Diamond, David M. Holtzman. Passive immunization with an anti-tau antibody in P301Smice reduces tau accumulation and improves motor deficits. Society for Neuroscience.Washington DC. Nov 15th – Nov 19th 2014.
5. Kiran Yanamandra, Hong Jiang, Tom Mahan, Susan Maloney, David Wozniak, Marc I. Diamond, David M. Holtzman. Passive immunization with an anti-tau antibodyreduces tau aggregation and decreases brain atrophy in P301S Tau transgenic mice.Neuroscience retreat, Grafton, IL. Sept 19th 2014.
6. Kiran Yanamandra, Najla Kfoury, Hong Jiang, Tom Mahan, Susan Maloney, David Wozniak, Marc I. Diamond, David M. Holtzman. Intracerebroventricular administration of anti-tau antibodies reduces pathology in P301S tau transgenic mice. Society for Neuroscience, San Diego, CA. Nov 9th – Nov 13th 2013.
7. Kiran Yanamandra, Najla Kfoury, Hong Jiang, Tom Mahan, Marc I. Diamond, David M. Holtzman. Effects of anti-tau antibodies on tau pathology in P301S human tau transgenic mice. Society for Neuroscience, New Orleans, LA. Oct 13th – Oct 17th 2012.
8. Kiran Yanamandra, Najla Kfoury, Hong Jiang, Tom Mahan, Marc I. Diamond, David M. Holtzman. Intracerebroventricular injection of anti-tau antibodies reduce tau pathology in P301S human tau transgenic mice. Leonard Berg Symposium, St. Louis MO. Sept 28th 2012.
9. Kiran Yanamandra, Najla Kfoury, Hong Jiang, Tom Mahan, Marc I Diamond, David M Holtzman. Characterization of anti-tau antibodies and their effects on tau pathology in P301S mice. Annual Retreat of Hope Center for Neurological Disorders. St.Louis MO. March 12th 2012.
10. Kiran Yanamandra, Ann-Christin Brorsson, Gian G Tartaglia, Anders Bergh, Fredrik Elgh, Ludmilla A. Morozova-Roche Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate. 1st Scandinavian amyloid symposium, Hemavan, Sweden. Sept 30th - Oct 2nd, 2009.
11. Kiran Yanamandra, Kristina Wilhelm & Ludmilla Morozova-Roche. Immune reactivity towards insulin, insulin amyloids and S100B in blood sera of Parkinson’s disease patients. EMBO Workshop on Cytotoxicity, Cell Death and the Immune System. Zaragoza, Spain, 17th – 20th September 2008.